[Assessment of plasma endothelin level measurement in systemic sclerosis]

J Schmidt1, D Launay, B Soudan

  • 1Service de Médecine Interne, Centre National de Référence des Atteintes Vasculaires de la Sclérodermie, Hôpital Claude-Huriez, CHRU de Lille, Université Lille-II, rue Michel-Polonovski, 59037 Lille cedex, France.

La Revue De Medecine Interne
|February 13, 2007
PubMed

Insights

Endothelin-1 (ET-1) levels are elevated in systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH). Higher ET-1 correlates with pulmonary arterial pressure, aiding PAH detection in SSc.

Area of Science:

  • Cardiovascular Research
  • Rheumatology
  • Pulmonology

Background:

  • Endothelin (ET)-1 is implicated in the pathogenesis of systemic sclerosis (SSc).
  • Understanding ET-1's role in SSc complications like pulmonary arterial hypertension (PAH) is crucial.

Purpose of the Study:

  • To assess plasma endothelin (ET)-1 levels in systemic sclerosis (SSc) patients.
  • To correlate ET-1 levels with clinical presentation and complications, specifically pulmonary arterial hypertension (PAH).

Main Methods:

  • Plasma ET-1 levels were measured in 63 SSc patients and 17 healthy controls.
  • Pulmonary function tests, HRCT, echocardiography, and right heart catheterization were used to screen for and confirm PAH.
  • Statistical analyses, including ROC curve, were performed to evaluate ET-1's diagnostic utility.

Main Results:

  • ET-1 levels were not significantly higher in SSc patients compared to controls.
  • Significantly higher ET-1 levels were observed in SSc patients with PAH (p=0.04) and those with anticentromere antibodies (p=0.03).
  • A positive linear correlation was found between ET-1 levels and systolic pulmonary arterial pressure (r=0.34, p=0.013).

Conclusions:

  • Plasma ET-1 levels are elevated in SSc patients with PAH and anticentromere antibodies.
  • ET-1 levels correlate with pulmonary arterial pressure, suggesting its potential as a biomarker.
  • Further prospective studies are warranted to evaluate ET-1 for detecting and monitoring pulmonary hypertension in SSc.
Abstract